Navigation Links
ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
Date:12/5/2007

SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has completed patient enrollment in its Phase 2 clinical trial of ANX-510, or CoFactor, for the treatment of advanced breast cancer.

"Data on the primary endpoint in this study, along with overall survival data from our Phase 2b study and available data from our discontinued Phase 3 study, all of which we expect in the second quarter of 2008, will expand our understanding of CoFactor's safety and efficacy," said Evan M. Levine, chief executive officer of ADVENTRX. "By mid-next year we should have greater insight into our ability to develop CoFactor in breast cancer and other indications."

The Phase 2 clinical trial is a single arm, multicenter study to evaluate the safety and efficacy of treatment with CoFactor plus 5-fluorouracil (5-FU) in advanced breast cancer patients who have failed anthracycline and taxane chemotherapies. Patients are treated with CoFactor followed by 5-FU administered by IV bolus weekly for 6 weeks, with tumor and safety assessments every 8 weeks. The primary endpoint for the study is objective response rate as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and secondary endpoints are duration of response, progression free survival, overall survival and incidence and severity of adverse events, as defined by the National Cancer Institute (NCI) Common Terminology Criteria. A total of 32 patients were enrolled in this study.

According to the American Cancer Society, breast cance
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... 19 Celsion Corporation (Nasdaq: CLSN ... ThermoDox® High Intensity Focused Ultrasound (HIFU) development program ... MR-guided Focused Ultrasound 2010 2nd International Symposium.  The ... as the rationale and support for future clinical ...
... Therapeutics, Inc. (BMT, Inc.), a new Seoul-based RNAi ... reduce significantly deleterious side effects triggered by conventional ... operations. The company is currently developing a novel ... on its asymmetric shorter-duplex siRNA (asiRNA) technology, originally ...
Cached Medicine Technology:Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium 2Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium 3BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors 2BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors 3
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2
... Rehabilitation Research and Development (JRRD) mainly analyses articles related ... sexuality, chronic pain and prosthetics research. ,Under ... pain associated with spinal cord injury the author of ... cord injury) reported chronic pain. He inquired about their ...
... are said to account for a large portion of ... to assess// this assumption in the Arab world. ... WHO World Mental Health (WMH) Survey Initiative, a nationally ... in Lebanon between September, 2002, and September, 2003, through ...
... School of Veterinary Medicine have established a national ... to humans and animals using medical records of ... Professor of Epidemiology. Larry Glickman of the School ... Pet Hospital, a nationwide chain of veterinary hospitals ...
... Pete Burns, following complaints of "sleep deprivation and exhaustion", has ... ,Burns, who is 46, had been residing at ... expensive pounds 450-a-night. There has been gossip doing the rounds ... the star out of his room for not paying his ...
... study by the New England Research Institutes in collaboration with ... or too little// are at a greater risk of developing ... based on studies done on over 1709 men, in the ... a period of 15 yrs. ,According to the ...
... A novel study conducted by Columbia University Medical ... for use in osteoarthritis, could be effective// in ... Until now, drug treatment with Cox-2 inhibitors or ... patients with chronic shoulder pain. ,Approximately ...
Cached Medicine News:Health News:JRRD Focuses On Issues Such As Spinal Cord Injury and Prosthetics 2Health News:JRRD Focuses On Issues Such As Spinal Cord Injury and Prosthetics 3Health News:A National Survey Revealed That Mental Disorders Are Common In Lebanon 2Health News:Pets As Disease Watchdogs 2Health News:Sodium Hyaluronate Shows Promise In Treatment Of Shoulder Pain 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: